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E-mail address: m.weisfelt@amc.uSummary Objectives: To assess cognitive outcome and quality of life in patients
with moderate disability after bacterial meningitis as compared to patients with
good recovery.
Methods: Neuropsychological evaluation was performed in 40 adults after pneumo-
coccal meningitis; 20 patients with moderate disability at discharge on the glasgow
outcome scale (GOS score 4) and 20 with good recovery (GOS score 5).
Results: Patients with GOS score 4 had similar test results as compared to patients
with GOS score 5 for the neuropsychological domains ‘intelligence’, ‘memory’ and
‘attention and executive functioning’. Patients with GOS score 4 showed less
cognitive slowness than patients with GOS score 5. In a linear regression analysis
cognitive speed was related to current intelligence, years of education and time
since meningitis. Overall performance on the speed composite score correlated
significantly with time since meningitis (K0.62; P!0.001). Therefore, difference
between both groups may have been related to a longer time between meningitis and
testing for GOS four patients (29 vs. 12 months; P!0.001).
Conclusions: Patients with moderate disability after bacterial meningitis are not at
higher risk for neuropsychological abnormalities than patients with good recovery. In
addition, cognitive slowness after bacterial meningitis may be reversible in time.
Q 2006 The British Infection Society. Published by Elsevier Ltd. All rights reserved.Introduction
Bacterial meningitis in adulthood remains an
important cause of mortality and long-termInfection Society. Published by
0 566 3842; fax: C31 20
va.nl (M. Weisfelt).neurological sequelae worldwide.1,2 Streptococcus
pneumoniae and Neisseria meningitidis are the
predominant cause of adulthood bacterial meningi-
tis, with an overall case fatality rate of 15–33 and
9%, respectively.1,2 Especially, meningitis due to
S. pneumoniae is associated with considerable
disability; hearing loss occurs in 22% of surviving
patients.1,2 Outcome is frequently assessed by the
glasgow outcome scale (GOS), which is a wellJournal of Infection (2006) 52, 433–439
www.elsevierhealth.com/journals/jinfElsevier Ltd. All rights reserved.
M. Weisfelt et al.434validated scale with good interobserver agree-
ment.2–4 The score on the GOS ranges from 1 to 5:
A score of 1 indicates death; 2, persistent
vegetative state; 3, severe disability; 4, moderate
disability (disabled but independent); 5, good
recovery.4 Although GOS score 5 implies good
recovery, cognitive impairment after meningitis in
this outcome group occurs frequently.5 In a
prospective study among 51 patients with good
recovery after bacterial meningitis, one out of four
patients after pneumococcal meningitis showed
significant cognitive slowness, which was related
with lower scores on general health and quality of
life.5 Neuropsychological evaluation in the outcome
group of moderately disability (GOS score 4) has not
been performed. Assumingly, these patients have
more severe disease and, therefore, are prone to
neuropsychological impairment. However, a lower
score on the GOS because of cranial nerve
abnormalities, such as hearing loss, does not
necessarily imply cognitive impairment. In this
study we assessed cognitive outcome and quality
of life in patients with moderate disability after
bacterial meningitis as compared to patients with
good recovery.Patients and methods
This study was based on the Dutch Meningitis
Cohort, a nationwide observational cohort study in
the Netherlands.2 In this study 696 episodes of
community-acquired acute bacterial meningitis,
confirmed by cerebrospinal fluid cultures, were
prospectively evaluated. Inclusion and exclusion
criteria, treatment, laboratory results and outcome
measures are described elsewhere.2 In summary,
patients were eligible in this study if they were
older than 16 years of age and were listed in the
database of the Netherlands Reference Laboratory
for Bacterial Meningitis from October 1998 to April
2002. This laboratory receives cerebrospinal fluid
isolates from approx. 85% of all patients with
bacterial meningitis in the Netherlands.2,6,7 The
laboratory provided daily updates of the names of
hospitals were patients with bacterial meningitis
had been admitted 2–6 days earlier. The physicians,
usually neurologists, were contacted and informed
about the study. Subsequently, patients or their
legal representative received written information
concerning the study and were asked to give written
informed consent; only participants from whom
consent was obtained participated in the study.
Information was collected by means of a case
record form. All patients underwent a neurologicalexamination at discharge, and outcomes were
graded by use of the GOS.Neuropsychological evaluation
We conducted a follow-up evaluation in adults
surviving pneumococcal meningitis with moderate
disability or good recovery on the GOS at discharge.
Neuropsychological evaluation was done at least 6
months after discharge and patients eligible for this
follow-up evaluation were patients aged 16–65
years with bacterial meningitis due to S. pneumo-
niae, who were discharged with GOS score 4 or 5.
Exclusion criteria were meningitis following head
trauma or neurosurgical intervention, serious ill-
nesses (other than meningitis), preexisting psychia-
tric disorders (including mental retardation) and
insufficient mastery of Dutch language. Four
cognitive domains were tested, as well as general
health and quality of life. These domains were
tested by the following test battery: (1) Intelligence,
current intelligence was tested by the Groningen
intelligence tests (GIT)—abbreviated version, con-
sisting of subtests for verbal and visuospatial
reasoning and numerical ability,8 premorbid intelli-
gence was tested by the Dutch adult reading test;9
(2) memory, the Rey’s auditory verbal learning test
(AVLT) was used to test verbal memory,10 figural
memory was tested by the subtest visual reproduc-
tion from the Wechsler memory scale revised (WMS-
R);10 (3) attention and executive functioning,
Trailmaking test, Stroop colour-word test, category
fluency, letter fluency, and the Wisconsin card
sorting test (WCST);8,10 (4) reaction speed, simple
and two-choice reaction time measured reaction
speed;10 (5) questionnaires, determination of
general health and quality of life were evaluated
by means of the RAND-36 questionnaire,11,12 the
profile of mood states (POMS) determined depress-
ive mood disorders.10 The tests are described more
extensively elsewhere.5
To explore the finding of differences in cognitive
speed between outcome groups, we formed a speed
composite score for each patient by calculation of
mean Z-transformed values of tests in which
cognitive speed is important (category and letter
fluency, numerical speed, trailmaking A and B,
visual and binary choice reaction tasks); a higher
score indicated worse performance.5Statistical methods
Test results were analysed by multivariate analysis
of variance for each neuropsychological domain
separately with covariates age and education when
Cognitive outcome after pneumococcal meningitis 435applicable. For non-parametric testing, Mann–
Whitney U, Chi-squared and Fisher’s exact statistics
were used; correlations are given by Pearson
correlation coefficients.Results
Demographic and clinical data
The characteristics of the Dutch meningitis cohort
are described elsewhere.2 In summary, mean age
was 50 years (SD 20) and 50% was male. The
causative organism was S. pneumoniae in 352
episodes (51%), N. meningitidis in 257 (37%), and
87 episodes (12%) were due to other bacteria.
Neurological examination at discharge was per-
formed in all patients surviving pneumococcal
meningitis: 175 patients (50%) had GOS score 5; 50
(14%) GOS 4; 17 (5%) GOS 3; 3 (1%) GOS 2; and 107
patients (30%) died (GOS 1). A total of 220 patients
were potentially eligible for cognitive testing; 55
consecutive patients were contacted for partici-
pation in this study. Forty patients were neuropsy-
chological evaluated (20 with GOS score 4 and 20
with GOS score 5); three patients had insufficient
mastery of Dutch language, six refused toTable 1 Baseline characteristics of patients with moderat
5) after pneumococcal meningitis
Time point, parameter
Baseline
Age at time of meningitis (years)
Gender (M:F)
Before admission
Symptoms before admission!24 h
Seizures
Presentation
Temperature O38 8C, headache and neck stiffness
Glasgow coma score !8
Laboratory









Data are number/numbers evaluated, age is meanGSD.
a PZ0.05 (Fisher’s exact test, two-tailed).
b P!0.001 (Fisher’s exact test, two-tailed).participate and three patients had serious somatic
illnesses. Demographic characteristics for patients
eligible for testing (nZ220) and participants of this
study (nZ40) were similar.
Clinical characteristics before admission and at
presentation were similar for both outcome groups
(Table 1), although the mean blood leucocyte count
was higher for patients with GOS score 5 (PZ0.05).
Overall, the classical triad of fever, headache and
neck stiffness was present in 29 patients (73%) and six
patients (15%) were comatose on admission. At
discharge, patients with GOS score 4 had more
neurological sequelae than patients with GOS score
5 (P!0.001). Cranial nerve palsies (hearing impair-
ment in all cases) were present in 14 patients (35%)
and cerebral focal deficits in five patients (13%). Of
patients with focal cerebral deficits, two had
hemiparesis and three had severe ataxia (without
hearing loss).
Demographic characteristics as gender, years of
education and premorbid intelligence level were
similar for both groups, although patients with GOS
score 4 were older at the moment of testing than
patients with GOS score 5 (Table 2). However, the
mean time between discharge and neuropsycho-
logical evaluation was significantly longer for
patients with GOS score 4 than for those with GOS
score 5 (29 vs. 12 months; P!0.001).e disability (GOS score 4) and good recovery (GOS score














M. Weisfelt et al.436Neuropsychological data
Multivariate analyses of covariance within each
neuropsychological domain showed significant
overall group differences for ‘reaction speed’
(Pillais’ trace; PZ0.02), but not for ‘intelligence’
(PZ0.16), ‘memory’ (PZ0.60) and ‘attention and
executive functioning’ (PZ0.09). Within the
domain of reaction speed, patients with GOS score
4 had superior scores on the binary choice reaction
task, compared with patients with GOS score 5
(Table 2).
Patients with GOS score 4 had significant lower
scores on the speed composite score (indicating
better performance) than patients with GOS score 5
(univariate test with covariates age and years of
education; PZ0.009). However, in a linear
regression analysis the speed composite score wasTable 2 Demographic characteristics and test scores in n
disability (GOS score 4) and good recovery (GOS score 5) af
Time point, parameter GOS sc
Baseline
Age at time of testing (years) 53.6G
Education (years) 12.7G
Time from discharge to testing (months) 29.3G
Premorbid intelligence (IQ) 98.9G
Intelligence (GIT)
Intelligence (IQ) 110.3G
Verbal reasoning (T-score)b 58.1G
Visuospatial reasoning (T-score) 53.6G
Numerical speed (T-score) 53.2G
Memory
Rey AVLT immediate (raw) 41.7G
Rey AVLT delayed (raw) 8.5G
Rey AVLT recognition (raw) 28.5G
WMS-R immediate (T-score) 59.5G
WMS-R delayed (T-score) 56.8G
Attention and executive functioning
Trailmaking A (T-score) 54.1G
Trailmaking B (T-score) 53.8G
Stroop colour-word test (T-score) 54.9G
Category fluency (T-score) 54.2G
Letter fluency (T-score) 50.1G
No. WCST categories (raw) 4.6G
No. WCST total errors (raw) 42.9G
No. WCST perseverative errors (raw) 23.6G
Reaction speed
Visual reaction task, dominant hand (ms) 280.3G
Visual reaction task, non-dominant hand (ms) 273.3G
Binary choice reaction task (ms) 445.3G
Data are meanGSD. IQ, intelligence quotient; GIT, Groningen intelli
test; WMS-R, Wechsler memory scale-revised; WCST, Wisconsin car
a Two-tailed P-values (t-test); GOS 4 patients vs. GOS 5 patients.
b T-score in population: Mean, 50; SD, 10. A higher score indicatesignificantly associated with current intelligence
(IQ; PZ0.03), education (PZ0.05) and time since,
meningitis (PZ0.05); associations with age and GOS
score were no longer significant. Overall perform-
ance of patients on the speed composite score
correlated significantly with time since meningitis
(K0.62; P!0.001), with covariates age, IQ and
education.
To evaluate the clinical relevance of test results
we defined a test score as clinically abnormal if
below one standard deviation from the mean of a
control group derived from a previous study.5 There
was a considerable heterogeneity between test
results within the group of patients with GOS score
4. For patients with cranial nerve palsies at
discharge the mean number of abnormal test results
was significantly lower compared to patients with
cerebral focal deficits (6 vs. 2; PZ0.001), andeuropsychological evaluation of patients with moderate
ter pneumococcal meningitis

























gence tests-abbreviated version; AVLT, auditory verbal learning
d sorting test.
s better performance.
Cognitive outcome after pneumococcal meningitis 437similar to GOS five patients and controls. Scores on
the speed composite score were similar for patients
with and without cerebral deficits at discharge.
Scores on general health and quality of life
(RAND-36) revealed lower scores on the item
‘physical functioning’ for patients with GOS score
4 compared with those with GOS score 5 (Table 3).
On other items no significant differences were
found. Patients with cerebral focal deficits had
lower scores on the item ‘physical functioning’
compared with patients without cerebral deficits
(score on item 55 vs. 78; PZ0.02). In addition,
scores on the item ‘physical functioning’ correlated
significantly with the speed composite score
(K0.35; PZ0.03). No differences were found on
the depression scale (POMS) for both outcome
groups and there was no significant correlation
between the item ‘depression’ on the POMS and the
results on the general speed composite score.Discussion
We found that adults with moderate disability after
pneumococcal meningitis are not at higher risk for
cognitive impairment than patients with good
recovery. Cognitive impairment occurs frequently
after bacterial meningitis. Other studies on cogni-
tive impairment among adults after bacterial
meningitis described cognitive slowness, impair-
ment of psychomotor performance, reduction in
visuoconstructive performance and higher scores
on depression scales.5,13–16 In a previous study we
found that even adults with good recovery after
pneumococcal meningitis are at significant risk for
cognitive slowness.5 In this study, 51 patients with
good recovery after meningococcal and pneumo-
coccal meningitis were examined. One out of four
patients with good recovery after pneumococcal
meningitis had significant cognitive impairment,Table 3 Scores on general health and quality of life (RAND-




Role impairment due to physical problems 65.8G44




Experienced general health 66.3G15
Data are meanGSD. RAND-36; higher score indicates better perfor
a Two-tailed P values (t-test); GOS 4 vs. GOS 5 patients.mainly consisting of cognitive slowness. Patients
after meningococcal meningitis had comparable
test scores as controls.5 In the present study,
patients with moderate disability due to focal
cerebral deficits were at higher risk for cognitive
impairment than patients without these sequelae.
Cognitive speed was related to time since
meningitis. In a linear regression model cognitive
speed was related to current intelligence, years of
education and time since meningitis. Although
patients with moderate disability were significantly
faster in time dependent tests than those with GOS
score 5, both groups had similar test scores after
correction for these variables. Although the differ-
ence in time interval since meningitis is a consider-
able shortcoming of our study, the relation between
cognitive slowness and time suggests that cognitive
slowness in adults after pneumococcal meningitis
may be in part reversible. The dynamic character of
sequelae in survivors of bacterial meningitis has
been described previously and implies that time
since illness is an important factor in follow-up
studies of adults after pneumococcal meningitis.14,17
Our finding is in agreement with results of a
prospective longitudinal cohort study on long-term
cognitive functioning in children after bacterial
meningitis.18 This study showed a significant
‘catch-up’ of children with cognitive impairment
after meningitis in executive function and cognitive
speed, which is largely comparable with our results.
Besides the difference in time between discharge
and neuropsychological evaluation there are sev-
eral other shortcomings in this study. The number
of patients that are neuropsychological evaluated is
small, which impaired statistical correction for the
number of tests. However, demographic features
for the participants and the eligible patients were
similar and results were compared to a control
group that was similar to features as age and
education. Nevertheless, our results should be36) for adults with moderate disability (GOS score 4) and
s










M. Weisfelt et al.438confirmed in a study with larger number of adults
with pneumococcal meningitis. Furthermore, mood
disorders are often present after meningitis and are
a potential confounder of cognitive test results.5
There was no significant correlation between
depressed mood and cognitive speed and scores
on the POMS depression-subscale were similar for
both outcome groups. Therefore, it is unlikely that
our results were confounded by depression.
Research on cognitive outcome in bacterial
meningitis is scarce and often with methodological
shortcomings. However, this follow-up evaluation is
designed for testing of multiple cognitive domains
and the population is relatively homogenous. Our
finding that loss of cognitive speed in adults after
pneumococcal meningitis may be reversible in time
is important information for patients presenting
with cognitive complaints after bacterial meningi-
tis. The association between the severity of
neurological sequelae after pneumococcal menin-
gitis and neuropsychological abnormalities is
weak.14 Since the categories of the GOS are very
broad, the GOS seems to be less adequate as an
instrument to evaluate cognitive outcome after
adulthood pneumococcal meningitis. Classification
of patients based on the nature of their neurological
sequelae, such as cranial-nerve palsies vs. cerebral
focal abnormalities may be more useful to identify
patients who are at risk for cognitive impairments.
Bacterial meningitis is a complex disorder in which
neurological injury is caused in part by the causative
organism and in part by the host’s own inflammatory
response. Recently, the European dexamethasone in
adulthood bacterial meningitis study showed that
adjunctive dexamethasone therapy reduces both
mortality and morbidity in adults with bacterial
meningitis.3 Ever since, adjunctive dexamethasone
is routine therapy for most adults with suspected
bacterial meningitis.19–21 In experimental meningitis,
dexamethasone as an adjunct to antibiotic treatment
aggravates neuronal damage in the hippocampal
formation22 and may potentiate ischemic injury to
neurons,23 so it is important to assess adverse
effects—e.g. whether steroids may prevent death
but worsen cerebral cortical functioning.20 There-
fore, further neuropsychological evaluation is
needed of patients with disability and good recovery
after bacterial meningitis, treated with and without
adjunctive dexamethasone therapy.Acknowledgements
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